Syndax Pharmaceuticals SNDX Increase in accrued expenses and other liabilities
Increase in accrued expenses and other liabilities at other companies
Other financials
Where this comes from
Reported directly by Syndax Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities.
The official record: Syndax Pharmaceuticals’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →
Ask your AI about Syndax Pharmaceuticals's increase in accrued expenses and other liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Syndax Pharmaceuticals's increase in accrued expenses and other liabilities?
- Syndax Pharmaceuticals (SNDX) reported increase in accrued expenses and other liabilities of -$28.35M in Q1 2026.
- How has Syndax Pharmaceuticals's increase in accrued expenses and other liabilities changed year-over-year?
- Syndax Pharmaceuticals's increase in accrued expenses and other liabilities decreased by 1019.2% year-over-year, from -$2.53M to -$28.35M.
- What is the long-term trend for Syndax Pharmaceuticals's increase in accrued expenses and other liabilities?
- Over 3 years (2021 to 2025), Syndax Pharmaceuticals's increase in accrued expenses and other liabilities has grown at a 147.9% compound annual growth rate (CAGR), from $2.77M to $42.17M.